PRA Health Sciences-Deep Lens partnership will hasten patient recruitment for cancer trials

 KUALA LUMPUR, Sept 21 -- PRA Health Sciences Inc and Deep Lens Inc have announced a new strategic relationship to accelerate patient access and recruitment for oncology clinical trials.

The partnership brings together best-in-class technologies that improve the identification, screening, and matching of cancer patients to precision-based clinical oncology trials on a global basis, with the combined solution being deployed to Microsoft Azure.

Deep Lens’ award-winning VIPER™ patient screening platform is a breakthrough technology deployed by cancer centres, integrated delivery networks, and community oncology networks, according to a statement.

The technology is aimed at identifying and matching oncology patients to life saving clinical trials, who would have otherwise fallen through the cracks and missed the opportunity to enroll.

“More than 14,000 oncology trials are currently recruiting patients, but estimates are that only three to five per cent of eligible patients actually participate,” said PRA Health Sciences Chief Scientific Officer, Kent Thoelke.

“The challenges facing clinical trial recruitment are multifaceted, and sponsors have been unable to determine where specific patients are in order to match them to studies -- that is about to change.”

“With Microsoft Azure behind PRA and Deep Lens, we believe this relationship could create a game-changing model in cancer research, not only for patient screening but for the development of just-in-time networks and other new business models.”

PRA Health Sciences is one of the world’s leading global contract research organisations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries.

For details, visit www.prahs.com.

-- BERNAMA